Pierre Gholam MD
@livermd.bsky.social
Hepatologist at University Hospitals of Cleveland and Professor at Case Western Reserve University SOM. Interested in liver cancer and all things #liversky
Husband, dad, wannabe world traveler and procrastinator.
Husband, dad, wannabe world traveler and procrastinator.
This thing is ded…
November 8, 2025 at 11:36 AM
This thing is ded…
@bsky.app I don’t know that I feel comfortable handing out very personal information to verify I’m an adult.
Please find a better way or I’m moving on.
Please find a better way or I’m moving on.
October 16, 2025 at 6:51 PM
@bsky.app I don’t know that I feel comfortable handing out very personal information to verify I’m an adult.
Please find a better way or I’m moving on.
Please find a better way or I’m moving on.
Effective rx for severe Alcohol Associated Steatohepatitis #ASH is the greatest unmet need in #hepatology
It fills hospital beds & kills people in their prime
Yet…
A cursory look shows >40 clinical stage ph2/3 #MASH studies vs (maybe) 3 for ASH
We need to get our priorities straight…
#liversky
It fills hospital beds & kills people in their prime
Yet…
A cursory look shows >40 clinical stage ph2/3 #MASH studies vs (maybe) 3 for ASH
We need to get our priorities straight…
#liversky
October 15, 2025 at 9:30 AM
Effective rx for severe Alcohol Associated Steatohepatitis #ASH is the greatest unmet need in #hepatology
It fills hospital beds & kills people in their prime
Yet…
A cursory look shows >40 clinical stage ph2/3 #MASH studies vs (maybe) 3 for ASH
We need to get our priorities straight…
#liversky
It fills hospital beds & kills people in their prime
Yet…
A cursory look shows >40 clinical stage ph2/3 #MASH studies vs (maybe) 3 for ASH
We need to get our priorities straight…
#liversky
Thrilled to be at the @davaoncology.bsky.social summit on GI malignancies. I had the pleasure of speaking on the topics of the intersection of incretins and cancer as well as the declining incidence of #HCC
#liversky
#liversky
September 20, 2025 at 7:54 PM
Thrilled to be at the @davaoncology.bsky.social summit on GI malignancies. I had the pleasure of speaking on the topics of the intersection of incretins and cancer as well as the declining incidence of #HCC
#liversky
#liversky
The voluntary withdrawal of Ocaliva by Intercept for PBC is not a cause for celebration.
It is certainly not an action that enhances the safety of the American public by protecting it from a nefarious, hepatotoxic drug.
Ocaliva is not troglitazone or bromfenac.
#liversky
It is certainly not an action that enhances the safety of the American public by protecting it from a nefarious, hepatotoxic drug.
Ocaliva is not troglitazone or bromfenac.
#liversky
September 11, 2025 at 7:30 PM
The voluntary withdrawal of Ocaliva by Intercept for PBC is not a cause for celebration.
It is certainly not an action that enhances the safety of the American public by protecting it from a nefarious, hepatotoxic drug.
Ocaliva is not troglitazone or bromfenac.
#liversky
It is certainly not an action that enhances the safety of the American public by protecting it from a nefarious, hepatotoxic drug.
Ocaliva is not troglitazone or bromfenac.
#liversky
More great news this time for European patients living with #MASH with F2/F3 fibrosis with the approval of #Rezdiffra™ (#resmetirom) by the @ema.europa.eu
Rezdiffra is included in the @easlnews.bsky.social
guidelines as FL therapy and is the first approved MASH medication in the EU.
#liversky
Rezdiffra is included in the @easlnews.bsky.social
guidelines as FL therapy and is the first approved MASH medication in the EU.
#liversky
August 20, 2025 at 12:08 AM
More great news this time for European patients living with #MASH with F2/F3 fibrosis with the approval of #Rezdiffra™ (#resmetirom) by the @ema.europa.eu
Rezdiffra is included in the @easlnews.bsky.social
guidelines as FL therapy and is the first approved MASH medication in the EU.
#liversky
Rezdiffra is included in the @easlnews.bsky.social
guidelines as FL therapy and is the first approved MASH medication in the EU.
#liversky
More #efruxifermin data this time in #MASH F2/F3 fibrosis @ 96 weeks
✅ Efficacy w/ dose dependent response (sort of) and NITs consistent
↔️ not crazy about mITT though it is mentioned no paired bx= non responders
⬇️ dose dependent reduction in bone mineral density
#liversky
✅ Efficacy w/ dose dependent response (sort of) and NITs consistent
↔️ not crazy about mITT though it is mentioned no paired bx= non responders
⬇️ dose dependent reduction in bone mineral density
#liversky
"Safety and efficacy of once-weekly efruxifermin versus placebo in metabolic dysfunction-associated steatohepatitis (HARMONY): 96-week results from a multicentre, randomised, double-blind, placebo-controlled, phase 2b trial.
Publié ce jour dans @thelancet.com
www.thelancet.com/journals/lan...
Publié ce jour dans @thelancet.com
www.thelancet.com/journals/lan...
Safety and efficacy of once-weekly efruxifermin versus placebo in metabolic dysfunction-associated steatohepatitis (HARMONY): 96-week results from a multicentre, randomised, double-blind, placebo-cont...
Efruxifermin resulted in greater improvements in fibrosis than placebo after 96 weeks,
warranting further investigation in phase 3 trials.
www.thelancet.com
August 18, 2025 at 10:46 PM
More #efruxifermin data this time in #MASH F2/F3 fibrosis @ 96 weeks
✅ Efficacy w/ dose dependent response (sort of) and NITs consistent
↔️ not crazy about mITT though it is mentioned no paired bx= non responders
⬇️ dose dependent reduction in bone mineral density
#liversky
✅ Efficacy w/ dose dependent response (sort of) and NITs consistent
↔️ not crazy about mITT though it is mentioned no paired bx= non responders
⬇️ dose dependent reduction in bone mineral density
#liversky
The @fda.gov just approved @novonordisk.bsky.social #wegovy on an accelerated path for #MASH F2/F3 fibrosis
We now have 2 approved drugs with different MOA and that’s great news for patients. I anticipate at least 5 more approvals in the next 5 years.
#liversky
We now have 2 approved drugs with different MOA and that’s great news for patients. I anticipate at least 5 more approvals in the next 5 years.
#liversky
August 16, 2025 at 7:01 PM
The @fda.gov just approved @novonordisk.bsky.social #wegovy on an accelerated path for #MASH F2/F3 fibrosis
We now have 2 approved drugs with different MOA and that’s great news for patients. I anticipate at least 5 more approvals in the next 5 years.
#liversky
We now have 2 approved drugs with different MOA and that’s great news for patients. I anticipate at least 5 more approvals in the next 5 years.
#liversky
Since #orforglipron is in the news, a helpful timeline:
There isn't a PDUFA (Prescription Drug User Fee Act) date set yet but @elilillyandcompany.bsky.social
has indicated they plan to submit for @US_FDA approval in Q3/4 2025
If approved, it could be available in Q4 2025 or 2026
#liversky
There isn't a PDUFA (Prescription Drug User Fee Act) date set yet but @elilillyandcompany.bsky.social
has indicated they plan to submit for @US_FDA approval in Q3/4 2025
If approved, it could be available in Q4 2025 or 2026
#liversky
August 1, 2025 at 1:01 AM
Since #orforglipron is in the news, a helpful timeline:
There isn't a PDUFA (Prescription Drug User Fee Act) date set yet but @elilillyandcompany.bsky.social
has indicated they plan to submit for @US_FDA approval in Q3/4 2025
If approved, it could be available in Q4 2025 or 2026
#liversky
There isn't a PDUFA (Prescription Drug User Fee Act) date set yet but @elilillyandcompany.bsky.social
has indicated they plan to submit for @US_FDA approval in Q3/4 2025
If approved, it could be available in Q4 2025 or 2026
#liversky
#Madrigal gains rights to CSPC’s #SYH-2086 as potential #MASH combo treatment.
SYH-2086 is an #orforglipron derivative (see last post)
An oral GLP-1 agonist + THR-B agonist would be an interesting combo that addresses broader cardiometabolic risk factors.
#liversky
SYH-2086 is an #orforglipron derivative (see last post)
An oral GLP-1 agonist + THR-B agonist would be an interesting combo that addresses broader cardiometabolic risk factors.
#liversky
Madrigal obtains rights to CSPC Pharmaceutical’s SYH-2086
Madrigal Pharmaceuticals Inc. and CSPC Pharmaceutical Group Ltd. have entered into an exclusive global license agreement for CSPC’s SYH-2086, a preclinical oral small-molecule glucagon-like peptide-1 ...
www.bioworld.com
July 31, 2025 at 2:00 AM
#Madrigal gains rights to CSPC’s #SYH-2086 as potential #MASH combo treatment.
SYH-2086 is an #orforglipron derivative (see last post)
An oral GLP-1 agonist + THR-B agonist would be an interesting combo that addresses broader cardiometabolic risk factors.
#liversky
SYH-2086 is an #orforglipron derivative (see last post)
An oral GLP-1 agonist + THR-B agonist would be an interesting combo that addresses broader cardiometabolic risk factors.
#liversky
The second @nejm.org #orforpligron paper is out.
There is no doubt that Oral GLP-1s are coming.
For #MASH, discontinuation rates will matter. 4-8% in T2DM (44w) vs. 10-17% in obesity (36w) which always seems higher.
How might our patients fare?
#liversky
There is no doubt that Oral GLP-1s are coming.
For #MASH, discontinuation rates will matter. 4-8% in T2DM (44w) vs. 10-17% in obesity (36w) which always seems higher.
How might our patients fare?
#liversky
Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist, in Early Type 2 Diabetes - PubMed
In adults with early type 2 diabetes, orforglipron significantly reduced the glycated hemoglobin level over a period of 40 weeks. (Supported by Eli Lilly; ACHIEVE-1 ClinicalTrials.gov number, NCT05971...
pubmed.ncbi.nlm.nih.gov
July 29, 2025 at 10:17 PM
The second @nejm.org #orforpligron paper is out.
There is no doubt that Oral GLP-1s are coming.
For #MASH, discontinuation rates will matter. 4-8% in T2DM (44w) vs. 10-17% in obesity (36w) which always seems higher.
How might our patients fare?
#liversky
There is no doubt that Oral GLP-1s are coming.
For #MASH, discontinuation rates will matter. 4-8% in T2DM (44w) vs. 10-17% in obesity (36w) which always seems higher.
How might our patients fare?
#liversky
We are looking forward to rolling out dual cut off reporting for liver stiffness measurement (LSM) and spleen stiffness measurement (SSM) which will aid in more accurately ruling in and out clinically significant portal hypertension (CSPH) and enhance clinical trial capability.
#liversky
#liversky
July 22, 2025 at 2:49 AM
We are looking forward to rolling out dual cut off reporting for liver stiffness measurement (LSM) and spleen stiffness measurement (SSM) which will aid in more accurately ruling in and out clinically significant portal hypertension (CSPH) and enhance clinical trial capability.
#liversky
#liversky
Jaume Bosch
No one, and I mean no one, made more seminal contributions to the measurement, interpretation & clinical applications of HVPG, the prognostic impact of CSPH and its rx.
Truly in the pantheon of all time greatest hepatologists and a kind, generous person on top.
RIP
#liversky
No one, and I mean no one, made more seminal contributions to the measurement, interpretation & clinical applications of HVPG, the prognostic impact of CSPH and its rx.
Truly in the pantheon of all time greatest hepatologists and a kind, generous person on top.
RIP
#liversky
July 17, 2025 at 2:54 AM
Jaume Bosch
No one, and I mean no one, made more seminal contributions to the measurement, interpretation & clinical applications of HVPG, the prognostic impact of CSPH and its rx.
Truly in the pantheon of all time greatest hepatologists and a kind, generous person on top.
RIP
#liversky
No one, and I mean no one, made more seminal contributions to the measurement, interpretation & clinical applications of HVPG, the prognostic impact of CSPH and its rx.
Truly in the pantheon of all time greatest hepatologists and a kind, generous person on top.
RIP
#liversky
This evening, @ohioliver.bsky.social awarded its inaugural Liver Champion award to Dr. Anthony Post “for decades of excellence, advocacy and commitment to northeast Ohioans with liver disease”
Thanks to all who joined us and made this a memorable event!
#liversky
Thanks to all who joined us and made this a memorable event!
#liversky
May 15, 2025 at 4:02 AM
This evening, @ohioliver.bsky.social awarded its inaugural Liver Champion award to Dr. Anthony Post “for decades of excellence, advocacy and commitment to northeast Ohioans with liver disease”
Thanks to all who joined us and made this a memorable event!
#liversky
Thanks to all who joined us and made this a memorable event!
#liversky
Join @ohioliver.bsky.social on May 14 at 630 pm at the Embassy suites hotel in Independence OH for Tavill Liver rounds. We will be honoring Dr. Anthony Post with our inaugural liver champion award!
#liversky
#liversky
May 12, 2025 at 10:25 PM
Join @ohioliver.bsky.social on May 14 at 630 pm at the Embassy suites hotel in Independence OH for Tavill Liver rounds. We will be honoring Dr. Anthony Post with our inaugural liver champion award!
#liversky
#liversky
Reposted by Pierre Gholam MD
🇬🇧 CALIBRE trial – D. Tripathi at #EASL2025
RCT: carvedilol vs VBL for 1º prevention in cirrhosis
🟰 No difference in bleeding or survival at 12 months
💊 Carvedilol safe, simpler & cost-effective
📉 Follow-up limited (12 mo), but extension planned
⚠️ Underpowered due to COVID
RCT: carvedilol vs VBL for 1º prevention in cirrhosis
🟰 No difference in bleeding or survival at 12 months
💊 Carvedilol safe, simpler & cost-effective
📉 Follow-up limited (12 mo), but extension planned
⚠️ Underpowered due to COVID
May 9, 2025 at 3:04 PM
🇬🇧 CALIBRE trial – D. Tripathi at #EASL2025
RCT: carvedilol vs VBL for 1º prevention in cirrhosis
🟰 No difference in bleeding or survival at 12 months
💊 Carvedilol safe, simpler & cost-effective
📉 Follow-up limited (12 mo), but extension planned
⚠️ Underpowered due to COVID
RCT: carvedilol vs VBL for 1º prevention in cirrhosis
🟰 No difference in bleeding or survival at 12 months
💊 Carvedilol safe, simpler & cost-effective
📉 Follow-up limited (12 mo), but extension planned
⚠️ Underpowered due to COVID
Highlights of @docberza.bsky.social talk on NITs @easlnews.bsky.social #easlcongress
We need to use @bavenocoop.bsky.social
dual stiffness cutoffs more often and u suspect this is the way of the future.
#liversky
We need to use @bavenocoop.bsky.social
dual stiffness cutoffs more often and u suspect this is the way of the future.
#liversky
May 9, 2025 at 3:11 PM
Highlights of @docberza.bsky.social talk on NITs @easlnews.bsky.social #easlcongress
We need to use @bavenocoop.bsky.social
dual stiffness cutoffs more often and u suspect this is the way of the future.
#liversky
We need to use @bavenocoop.bsky.social
dual stiffness cutoffs more often and u suspect this is the way of the future.
#liversky
Exhibitor booths are not usually meeting highlights but this is an exception. Kudos to @boehringerglobal.bsky.social
on this artistic rendition on the theme of liver health and disease @easlnews.bsky.social #EASLCongress
#livertwitter
on this artistic rendition on the theme of liver health and disease @easlnews.bsky.social #EASLCongress
#livertwitter
May 7, 2025 at 12:51 PM
Exhibitor booths are not usually meeting highlights but this is an exception. Kudos to @boehringerglobal.bsky.social
on this artistic rendition on the theme of liver health and disease @easlnews.bsky.social #EASLCongress
#livertwitter
on this artistic rendition on the theme of liver health and disease @easlnews.bsky.social #EASLCongress
#livertwitter
I would venture to say that for @umich.edu this was a swing and a miss.
Always be weary of people who chase after an even more outrageous compensation than the one they are getting and are willing to change jobs like they change underwear…
Always be weary of people who chase after an even more outrageous compensation than the one they are getting and are willing to change jobs like they change underwear…
University President Who Shut Down D.E.I. Efforts Is Recruited to Florida
www.nytimes.com
May 6, 2025 at 6:34 AM
I would venture to say that for @umich.edu this was a swing and a miss.
Always be weary of people who chase after an even more outrageous compensation than the one they are getting and are willing to change jobs like they change underwear…
Always be weary of people who chase after an even more outrageous compensation than the one they are getting and are willing to change jobs like they change underwear…
Amsterdam bound to attend @easlnews.bsky.social #easlcongress
Looking forward to learning, connecting with old friends and making new ones!
#liversky
Looking forward to learning, connecting with old friends and making new ones!
#liversky
May 5, 2025 at 7:11 PM
Amsterdam bound to attend @easlnews.bsky.social #easlcongress
Looking forward to learning, connecting with old friends and making new ones!
#liversky
Looking forward to learning, connecting with old friends and making new ones!
#liversky
Out of all current FDA approvals: DM, overweight/obese, death RR in CV disease, delay in renal disease progression in CV/DM and OSA…
PAYERS ONLY RELIABLY COVER DM
Are PBMs suddenly going to loosen up their purses because there is a #MASH indication?
I’ll believe it when I see it…
#liversky
PAYERS ONLY RELIABLY COVER DM
Are PBMs suddenly going to loosen up their purses because there is a #MASH indication?
I’ll believe it when I see it…
#liversky
May 2, 2025 at 3:43 AM
The full ESSENCE dataset of #semaglutide in #MASH is published. The results at 72 weeks look great. Additional cardiometabolic benefits are definitely a plus.
An sNDA is said to be forthcoming in Q3/4.
#liversky
An sNDA is said to be forthcoming in Q3/4.
#liversky
Phase 3 Trial of Semaglutide in Metabolic Dysfunction–Associated Steatohepatitis | NEJM
Semaglutide, a glucagon-like peptide-1 receptor agonist, is a candidate for the treatment
of metabolic dysfunction–associated steatohepatitis (MASH). In this ongoing phase
3, multicenter, randomize...
www.nejm.org
May 2, 2025 at 3:34 AM
The full ESSENCE dataset of #semaglutide in #MASH is published. The results at 72 weeks look great. Additional cardiometabolic benefits are definitely a plus.
An sNDA is said to be forthcoming in Q3/4.
#liversky
An sNDA is said to be forthcoming in Q3/4.
#liversky
A delightful assortment of Lebanese mezze at Sky Lounge Parma today!
April 28, 2025 at 3:11 AM
A delightful assortment of Lebanese mezze at Sky Lounge Parma today!
Early returns on my #resmetirom #rezdiffra #MASH patients at 1 year. So far 7/8 patients reasessed with LSM have a 30% or greater reduction. Hopefully we start getting some real world data to complement the open label trial.
#liversky
#liversky
April 15, 2025 at 12:02 PM
Early returns on my #resmetirom #rezdiffra #MASH patients at 1 year. So far 7/8 patients reasessed with LSM have a 30% or greater reduction. Hopefully we start getting some real world data to complement the open label trial.
#liversky
#liversky